---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218134"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2026-05-12T11:00:16+00:00"
generated_at: "2026-05-12T11:17:31.820315+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CalciMedica reports Q1 net income $5.0M; FDA feedback on Auxora pivotal program expected Q2 2026

## Summary
- Net income $5.0M ($0.31 basic) vs net loss $5.0M a year ago; cash $8.2M as of March 31, 2026.
- R&D expenses $3.5M, G&A $2.1M; other income $10.6M from fair value adjustments on warrants and note.
- FDA feedback on pivotal program design for Auxora in acute pancreatitis expected in Q2 2026.
- IND submission for oral CRAC inhibitor CM5480 in pulmonary hypertension anticipated in 2027.
- Phase 2b CARPO results published: Auxora showed 100% reduction in new-onset severe respiratory failure (p<0.05).

## SEC filing metadata
- accession: 0001193125-26-218134
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2026-05-12T11:00:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/0001193125-26-218134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/ck0001534133-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218134
- JSON: https://secwatch.observer/filing/0001193125-26-218134.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218134.txt

## Key facts
- Earnings Releases
  CalciMedica, Inc. reported first quarter ended March 31, 2026 results: net income Net income was $5.0 million, EPS $0.31 per basic share and $0.30 per diluted share.
  - Period: first quarter ended March 31, 2026
  - Net income: Net income was $5.0 million
  - EPS: $0.31 per basic share and $0.30 per diluted share
  - Result: reported results
  source text: Net income was $5.0 million, or $0.31 per basic share and $0.30 per diluted share, for the three months ended March 31, 2026, compared to a net loss of $5.0 million, or $0.36 per basic
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/0001193125-26-218134-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.